U.S. market Closed. Opens in 5 hours 51 minutes

INVO | INVO Bioscience, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for INVO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (21%)

Company Industry
P/E Ratio (TTM) -0.42 47.43
PEG Ratio (TTM) -0.01 -0.37
P/S Ratio (TTM) 0.56 6.17
P/B Ratio (TTM) 2.21 6.03
P/FCF Ratio (TTM) -0.82 41.68
Price to 5YR AVG Earnings Ratio -0.06 58.57
Price to 5YR AVG FCF Ratio -0.74 34.18

Profitability (0%)

Company Industry
ROA (TTM) -39.29% 5.30%
ROE (TTM) -1,073.76% 28.25%
Net Profit Margin (TTM) -122.80% 8.25%
ROIC 5YR AVG -452.17% 6.60%

Growth (30%)

4QTR AVG 3YR AVG 5YR AVG
EPS 3.75% -492.34% -289.82%
Revenue 70.23% 156.85% 131.54%
Net Income -9.04% -78.43% -54.55%
Cash Flow -82.07% -54.94% -29.27%

Health (7%)

Company Industry
Current Ratio (TTM) 0.30 2.90
Quick Ratio (TTM) 0.27 2.17
D/E Ratio (TTM) 2.10 0.61
Interest Coverage (TTM) -4.83 22.17
Piotroski F-Score 1 6
Altman Z-Score N/A 7.62
LTL to 5YR AVG FCF -1.55 3.53
Shares Outstanding Growth 5YR AVG 36.83% 1.60%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙